• Search
  • Advanced Search
Korean J Intern Med > Volume 41(2); 2026 > Article
EDITORIAL
Hemato-oncology
Korean J Intern Med. 2026;41(2):183-185.         doi: https://doi.org/10.3904/kjim.2025.054
A bridge, not a destination: clarifying the role of polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma
Ho-Young Yhim
Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea
Corresponding Author: Ho-Young Yhim  , Tel: +82-63-250-2523, Fax: +82-63-255-1609, Email: yhimhy@jbnu.ac.kr
Received: January 29, 2026;   Accepted: February 4, 2026.
Share :  
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 2 View
  • 1 Download
Related articles

Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma2026 March;41(2)

Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?2019 July;34(4)

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6792    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2026 by Korean Association of Internal Medicine.

Close layer
prev next